SEngine Precision Medicine

Seattle, United States Founded: 2015 • Age: 11 yrs
Precision medicine platform is offered using patient-derived organoids.

About SEngine Precision Medicine

SEngine Precision Medicine is a company based in Seattle (United States) founded in 2015.. SEngine Precision Medicine has raised $27.35 million across 5 funding rounds from investors including Washington Research Foundation and Alethea. SEngine Precision Medicine offers products and services including PARIS Test and Drug Development Platform. SEngine Precision Medicine operates in a competitive market with competitors including GRAIL, Color, Earli, RainDance and NovellusDx, among others.

  • Headquarter Seattle, United States
  • Sectors
    Healthcare
  • Email
    ***********
  • Phone
    *********
  • Website
    *********
  • Social
    *********
Operational Areas
Healthcare → Healthcare Products & Supplies
Key Metrics
  • Annual Revenue
  • Net Profit
  • EBITDA
  • Total Equity Funding
    $27.35 M (USD)

    in 5 rounds

  • Latest Funding Round
    $600 K (USD), Series A

    Mar 10, 2023

  • Investors
  • Employee Count
    Employee Count
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal

Products & Services of SEngine Precision Medicine

SEngine Precision Medicine offers a comprehensive portfolio of products and services, including PARIS Test and Drug Development Platform. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.

Primary

Tests cancer drugs on tumor organoids for personalized treatment options.

Leverages test data to accelerate new cancer drug creation processes.

People of SEngine Precision Medicine
Headcount 10-50
Employee Profiles 5
Board Members and Advisors 9
Employee Profiles
People
Shalini Pereira
CLIA Laboratory Director
People
Carla Grandori
Co-Founder & CEO
People
Alex Rajewski
Bioinformatics Scientist
People
Robert Diaz
Director Of Clinical Operations

Unlock access to complete

Board Members and Advisors
people
William Grady
Scientific Advisor
people
Jonathan Baell
Scientific Advisor
people
Siddhartha Mukherjee
Scientific Advisor
people
Tony Hsu
Board Member

Unlock access to complete

Funding Insights of SEngine Precision Medicine

SEngine Precision Medicine has successfully raised a total of $27.35M across 5 strategic funding rounds. The most recent funding activity was a Series A round of $600 thousand completed in March 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

  • Total Funding
  • Total Rounds 5
  • Last Round Series A — $600,000
  • First Round

    (29 Oct 2018)

  • Investors Count 2
Date Amount Transaction Name Valuation Lead Investors Investors
Mar, 2023 Amount Series A - SEngine Precision Medicine Valuation

investors

Jul, 2022 Amount Series A - SEngine Precision Medicine Valuation Washington Research Foundation
Oct, 2019 Amount Series A - SEngine Precision Medicine Valuation

investors

Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Investors in SEngine Precision Medicine

SEngine Precision Medicine has secured backing from 2 investors, including venture fund and institutional investors. Prominent investors backing the company include Washington Research Foundation and Alethea. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.

All
Venture Fund
Institutional
Investor Description Founded Year Domain Location
Early-stage venture capital is provided to US companies across sectors.
Founded Year Domain Location
Alethea Capital Management, LLC is engaged in investment advisory services.
Founded Year Domain Location
Investor Description Founded Year Domain Location
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
Founded Year Domain Location
Startup ecosystems are ignited through strategic investments by Signite Partners.
Founded Year Domain Location
Venture capital is directed toward companies in multiple sectors.
Founded Year Domain Location
Venture capital is invested in cybersecurity, fintech, and AI startups.
Founded Year Domain Location

Investments & Acquisitions by SEngine Precision Medicine

Investments
Company Name Description Domain Location Founded Year Amount
Bionic investment advisor platform
2016
Fine Asian gourmet food is offered by an internet-first restaurant.
2016
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
2014
Fine Asian gourmet food is offered by an internet-first restaurant.
2016

Financial Statements - SEngine Precision Medicine

Tata Steel revenue growth over time
Tata Steel profit and loss trends over time
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Sengine Precision Medicine Comparisons

Employees
+
Add Comparison
Available on Premium

Competitors of SEngine Precision Medicine

SEngine Precision Medicine operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as GRAIL, Color, Earli, RainDance and NovellusDx, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.

Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Circulating tumor DNA is screened for early cancer detection.
domain founded_year HQ Location
Cancer care is delivered through a virtual clinic by Color.
domain founded_year HQ Location
Early cancer detection tests are developed using synthetic biomarkers.
domain founded_year HQ Location
Developer of nucleic acid detection and quantification systems
domain founded_year HQ Location
Developer of technology for precision cancer diagnosis and therapies
domain founded_year HQ Location
Tumor response to cancer therapies is monitored via specialized assays.
Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Multiple services are booked via an app-based platform.
domain founded_year HQ Location
On-demand services are booked through an app-based platform.
domain founded_year HQ Location
App based platform offering on demand delivery and ride-hailing services
domain founded_year HQ Location
Operates an on-demand hyperlocal delivery app for food and groceries.

Frequently Asked Questions about SEngine Precision Medicine

When was SEngine Precision Medicine founded?

SEngine Precision Medicine was founded in 2015 and raised its 1st funding round 3 years after it was founded.

Where is SEngine Precision Medicine located?

SEngine Precision Medicine is headquartered in Seattle, United States. It is registered at Seattle, Washington, United States.

Is SEngine Precision Medicine a funded company?

SEngine Precision Medicine is a funded company, having raised a total of $27.35M across 5 funding rounds to date. The company's 1st funding round was a Series A of $8.65M, raised on Oct 29, 2018.

What does SEngine Precision Medicine do?

SEngine Precision Medicine was founded in 2015 in Seattle, United States, within the biotechnology sector. A platform for precision medicine is provided, relying on patient-derived organoids to identify novel drug targets. Synthetic lethality concepts are integrated to address undruggable oncogenes and tumor suppressor losses. Targeted drug candidates are screened on human disease samples through in vitro clinical trials, supporting pipeline acceleration.

Who are the top competitors of SEngine Precision Medicine?

SEngine Precision Medicine's top competitors include GRAIL, Earli and Color.

What products or services does SEngine Precision Medicine offer?

SEngine Precision Medicine offers PARIS Test and Drug Development Platform.

Who are SEngine Precision Medicine's investors?

SEngine Precision Medicine has 2 investors. Key investors include Washington Research Foundation, and Alethea.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available